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Abstract
Free Water Imaging is a novel diffusion magnetic reasonance imaging (MRI) method that is able
to separate changes affecting the extracellular space from those that reflect changes in neuronal
cells and processes. A previous Free Water Imaging study in schizophrenia identified significantly
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greater extracellular water volume in the early stages of the disorder; however, it’s clinical and
functional sequelae have not yet been investigated. Here, we applied Free Water Imaging to a
larger cohort of 63 first-episode patients with psychosis and 70 healthy matched controls to better
understand the functional significance of greater extracellular water. We used diffusion MRI data
and the Tract-Based Spatial Statistics analytic pipeline to first analyze fractional anisotropy (FA),
the most commonly employed metric for assessing white matter. This comparison was then
followed by Free Water Imaging analysis, where two parameters, the fractional volume of
extracellular free-water (FW) and cellular tissue FA (FA-t), were estimated and compared across
the entire white matter skeleton between groups, and correlated with cognitive measures at
baseline and following 12 weeks of antipsychotic treatment. Our results indicated lower FA across
the whole brain in patients compared to healthy controls that overlap with significant increases in
FW, with only limited decreases in FA-t. In addition, higher FW correlated with better
neurocognitive functioning following 12 weeks of antipsychotic treatment. This is the first study to
suggest that an extracellular water increase during the first-episode of psychosis, which may be
indicative of an acute neuroinflammatory process, and/or cerebral edema may predict better
functional outcome.

A. Introduction

Author Manuscript

Schizophrenia (SZ) is a chronic psychiatric disorder that affects almost 1% of the population
(1). While the etiology of SZ is still unclear, it has been posited to be a disorder of
“dysconnectivity,” such that many of the behavioral symptoms and cognitive deficits in SZ
can be explained by aberrations in the communication of information among cortical areas
(2,3). In recent years, increased focus has been placed on cerebral white matter connections
because they are purported to play a central role in SZ pathophysiology (4). The
involvement of white matter pathology is supported by postmortem and histological studies
that identify abnormalities in myelin and myelin-related genes in patients with SZ (5,6).

Author Manuscript

The application of diffusion tensor imaging (DTI) has permitted the interrogation of
microstructural properties of white matter in vivo (7). The most common finding in SZ is
lower fractional anisotropy (FA) in the corpus callosum, and the majority of fronto-temporal
fasciculi (8,9). Lower FA in patients has frequently been interpreted to reflect changes in the
“integrity” of myelinated connections. There is a high degree of variability, however, in
reported findings, likely due to the fact that DTI indices (e.g., FA) are sensitive to a range of
biological pathologies, such as axonal degeneration, demyelination, or increases in
extracellular water volume (10). The lack of specificity of FA necessitates the development
of metrics to distinguish among white matter pathologies that may underlie the neurobiology
of SZ.
A promising new development is Free Water Imaging, which uses a two-compartment model
of water diffusion from diffusion-weighted images (DWIs)(11). This method increases the
specificity of the traditional single-compartment model, DTI, by separating the contribution
of freely diffusing extracellular water from water in the proximity of brain cells and their
processes. Free Water Imaging calculates two parameters. The first, FW, which reflects the
fractional volume of unrestricted free-water, has been proposed to serve as an indicator of
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extracellular changes that are being driven by pathologies such as atrophy, cerebral edema,
or neuroinflammation (11). The second is the residual diffusion signal from restricted/
hindered water, that is modeled as a diffusion tensor and termed fractional anisotropy of the
“tissue” (FA-t), reflecting the microstructure of cells and their processes. By separating the
extracellular free-water component from the “tissue” component, Free Water Imaging
provides greater sensitivity to detect structural changes between groups through both
measurements of extracellular pathology, as well as lowering the variability in the tissuerelated parameter, FA-t, comparing to the traditional FA metric (12).

Author Manuscript

Using the Free Water Imaging approach in a cohort of recent-onset schizophrenia patients
we showed that frequently reported widespread reductions in FA (see reviews(8,9)) can be
explained by significant increases in FW (13). Interestingly, there were only circumscribed
reductions in FA-t in frontal lobe white matter (13), leading to the conclusion that
individuals in the early stages of schizophrenia were exhibiting a global increase of FW,
indicating extracellular changes, and not widespread myelin deterioration, as previously
suggested (8,9). Evidence from recent PET studies describing increased levels of activated
microglia and reactive astrocytes coupled with reports of greater levels of pro-inflammatory
cytokines in blood or cerebrospinal fluid in patients have led to the hypothesis that these
extracellular changes are consistent with a neuroinflammatory response (14–16). Moreover,
these studies further suggest that such a response is present at earlier, more acute stages of
schizophrenia, than widespread axonal degeneration, which has been demonstrated to be
more pronounced at later stages of the disorder (17).
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The primary goal of the current study was to investigate whether increases in extracellular
FW would be observed among patients experiencing a first episode of psychosis studied
early in the course of illness and prior to extensive pharmacologic intervention. Moreover,
because the functional significance of the extracellular FW response remains largely
unknown, an additional goal was to examine the neurocognitive and clinical correlates of
FW in patients.

B. Methods
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Subjects—Sixty-three patients experiencing a first-episode of psychosis (FEP) were
recruited from the inpatient service at The Zucker Hillside Hospital in Glen Oaks, NY, and
enrolled in an NIMH-funded double blind randomized controlled trial comparing
aripiprazole (n=29) versus risperidone (n=34)(18). All patients had 2 weeks or less of
cumulative lifetime exposure to antipsychotics prior to entry into the clinical trial. All
patient (lifetime) diagnoses were based on the SCID for Axis I DSM-IV Disorders and
included schizophrenia (undifferentiated = 25 and paranoid = 15), schizophreniform disorder
(n=15), schizoaffective disorder (n=1), or psychosis NOS (n=7). On average, patients had a
total lifetime exposure of 6.3 (SD = 7.3) days of antipsychotic treatment prior to the baseline
scan and had received their MRI exam within an average of three days (range = −23 to 30
days) of entry into the clinical trial. Twenty-one patients were antipsychotic drug-naïve at
the time of the baseline scan. Mean age at first psychotic symptoms was 19.1 years (SD =
4.6); data were unavailable for three patients.
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We recruited 70 healthy volunteers from advertisements to match the demographic
distributions of patients. Exclusion criteria for healthy subjects included the presence of any
lifetime history of a major mood or psychotic disorder as determined by clinical interview
using the SCID-NP. Exclusion criteria for all study participants included MR imaging
contraindications, and any serious medical disorder that could affect brain functioning or
mental retardation.
This study was approved by the local Institutional Review Board and written informed
consent was obtained from all study participants or their parents in the case of minors. All
minors provided written informed assent to participate in the study.

Author Manuscript

Treatment Trial Antipsychotic Titration Schedule—Research psychiatrists followed
a flexible dosing titration schedule. The initial daily dose for patients in the treatment trial
was 5 mg for aripiprazole and 1 mg for risperidone, which was increased after three days of
treatment with further adjustments made every 1–3 weeks until the patient improved,
developed side effects that precluded a dose increase, or reached a maximum daily dose of
30 mg of aripiprazole or 6 mg of risperidone. Patients were not allowed to receive
antidepressants, mood stabilizers, or any other psychotropic medication.
Clinical Assessments—Patients completed the 18-item Brief Psychiatric Rating Scale –
Anchored version (BPRS-A(19)) and we derived a total score by summing all items. The
average Brief Psychiatric Rating Scale Score was 43.6 (SD = 8.6) at the time of baseline
scanning and 27.7 (SD = 8.1) at follow-up.
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Cognitive Assessments—We administered the MATRICS Consensus Cognitive Battery
(MCCB) to patients at baseline and following 12-weeks of antipsychotic treatment. An
overall score was computed as the average of the individual domains. At baseline, of the
total 63 FEP patients included in this study, 57 FEP patients (43M/14F) completed the entire
MCCB, while six FEP patients (3M/3F) did not. At the 12-week follow-up, of the 57 that
completed the entire baseline MCCB, 39 FEP patients (28M/11F) returned and completed
the entire MCCB, while 18 FEP patients (15M/3F) did not. We did not detect any significant
differences in baseline values of age, sex, handedness, years of education, total BPRS score,
and global ratings of negative symptoms between individuals with and without NP data at
the 12-week time point.
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Diffusion MR Procedures—Diffusion MR scans were acquired at the North Shore
University Medical Center on a GE 3T HDx scanner. A total of 36 diffusion weighted
images (DWIs) were obtained from each subject at baseline, including 31 volumes with
diffusion gradients applied along 31 non-parallel directions with b = 1000 s/mm2 and, and 5
volumes without diffusion weighting (b = 0). Each volume consisted of 51 contiguous 2.5
mm axial slices acquired parallel to the anterior-posterior commissural line using a ramp
sampled, spin-echo, single shot echo-planar imaging method (TR = 14000ms, TE =
<84.8ms, matrix = 128x128, FOV = 240mm).
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Free Water Imaging—The Free Water Imaging analysis pipeline has been previously
described (13,17). Briefly, diffusion-weighted images (DWIs) were corrected for motion and
eddy-current artifacts by means of affine registration with a b=0 reference volume (FLIRT,
FSL, Oxford) as in our prior work (13,17) and subsequently masked to exclude non-brain
areas. We excluded 7 subjects with high motion from analysis (>2 SD from the mean)(11).
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FW maps were created by fitting aligned DWIs with a two-compartment model comprised
of a free-water compartment and a “tissue” compartment as described previously (11).
Briefly, the free-water compartment extracts the contribution of water molecules that diffuse
freely in the extracellular space, quantified by a single parameter called FW, which stands
for the fractional volume of free-water. The second compartment describes the behavior of
water molecules that are affected by proximity to cells, and are modeled utilizing a diffusion
tensor. This produces two voxel-wise maps, one representing FW and one representing the
FA values that are corrected for FW (FA-t).
White Matter Processing—We employed the tract-based spatial statistics (TBSS)
pipeline (20) and the FA target image and skeleton that was created by the Enhanced
Neuroimaging Genetics by Meta Analysis (ENIGMA) DTI Working Group at the University
of Southern California, all of which are publicly available (http://enigma.ini.usc.edu/
ongoing/dti-working-group)(21). We utilized the ENIGMA processing stream to allow for
greater generalizability of results across studies, including an ongoing, multi-site metaanalysis of diffusion data from schizophrenia patients across 22 sites (22). Using this
pipeline, we projected the FA, FA-t, and FW maps onto the skeleton to perform statistical
analyses.
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Statistical Analysis
Group comparisons were performed using a nonparametric permutation-based test
(Randomise, FSL) with a threshold free cluster enhancement (TFCE) and family-wise error
correction (23,24). The data were then tested against an empirical null distribution, which
was generated by 5000 permutations for each contrast, resulting in statistical maps that are
corrected for multiple comparisons across the whole brain and significance at a threshold of
p < 0.05. Age and sex were included as covariates. As there was no significant difference
between groups for the calculated motion parameter (t = 0.884, p = 0.3781; Means: FEP =
0.53; HC = 0.52) it was not included as a covariate. For the purpose of investigating
correlates of diffusion signal, significant clusters were averaged to create a single cluster
mean for FA-t and FW for each subject.

Author Manuscript

One additional set of voxel-wise statistical comparisons was computed utilizing the
previously mentioned nonparametric permutation-based test (Randomise, FSL) to determine
the possible effects of medication on our findings. We compared FA-t and FW values
between medicated FEP patients and medication-naïve FEP patients with age and sex as
covariates.
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We correlated baseline averaged FA, FA-t and FW values for patients with the Overall score
on the MCCB at baseline and 12 weeks following treatment. If the Overall MCCB score was
significantly correlated with FA, FW or FA-t at baseline or 12 weeks, we then examined the
individual domains and corrected for multiple comparisons (Bonferroni adjusted
significance threshold: p < 0.007). Baseline averaged FA, FA-t and FW values in FEP
patients were also correlated with scores on the BPRS at baseline and 12 weeks.
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To explore sex effects in both healthy controls (HC) and FEP patients, we conducted a posthoc analysis where we divided the entire sample into four groups: HC Females (n=24), HC
Males (n=46), FEP Females (n=17), and FEP Males (n=46). We calculated a one-way
ANCOVA to test the main effect of group while controlling for age. We utilized Tukey’s
Honest Significant Difference test to calculate post-hoc pairwise comparisons between
means of each group with p-values that were corrected for the total number of comparisons
to the confidence level of 0.95 (p < 0.05) using family-wise error rates.

C. Results
There were no significant differences between FEP and the HC in distributions of age, sex,
and handedness, but groups did differ in education (Table 1). There were no significant
differences in demographic variables between patients treated with aripiprazole versus
risperidone (18).
C1. Extent and Nature of Diffusion Changes in First-Episode Schizophrenia Patients
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The FEP group showed significantly (p < 0.05) lower FA extending over most of the white
matter skeleton compared to controls (Figure 1). A significant globalized increase in FW (p
< 0.05) in FEP compared to HC was also observed (Figure 1). As illustrated in Figure 1,
there is almost complete overlap between the regions with lower FA and those with higher
FW in FEP compared to HC, suggesting that FA changes can be mostly explained by
alterations in the extracellular free-water compartment. In contrast, the FA-t voxel-wise
analysis produced only circumscribed differences between FEP and HC. Significant
reductions (p < 0.05) in FA-t in FEP were found in the body and genu of the corpus
callosum and the left superior and posterior corona radiata as well as the left superior
longitudinal fasciculus (Figure 1).
We compared the FW and FA-t values between medicated FEP (n=42) and medication-naïve
FEP (n=21) patients and found no significant differences in either FW or FA-t (p > 0.05),
suggesting that medication status at baseline does not significantly contribute to the
observed group differences.
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C2. Cognitive Correlates of Extracellular FW Increase in FEP Patients
At baseline, FA, FA-t and FW in the FEP were not related to overall MCCB performance.
However, baseline FW values in patients showed a significant positive correlation with
overall MCCB performance 12 weeks following treatment (Pearson’s r = 0.4712, p =
0.0025) (Figure 2). Of the seven domains, all but the social cognition domain demonstrated a
positive correlation with baseline FW values; however, only two domains survived
Bonferonni correction (see Supplementary Figure 1): Working Memory (Pearson’s r =
Mol Psychiatry. Author manuscript; available in PMC 2017 September 28.
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0.4287, p = 0.0065), and Verbal Memory (Pearson’s r = 0.5159, p = 0.0008). This finding
was unique to FW, as FA and FA-t at baseline did not predict performance on the overall
MCCB. Baseline average FA, FW and FA-t values did not correlate significantly with BPRS
scores at either baseline or 12 weeks.
C4. Sex Effects

Author Manuscript

The results of the exploratory one-way ANCOVA reveal a significant group difference in
FW (F = 9.32, p < 0.0001; Figure 3). Post-hoc pairwise comparisons using Tukey’s HSD for
FW values (Table 2) showed significant differences for the following comparisons: FEP
Females-HC Females (p = 0.0004), FEP Males-HC Males (p = 0.02), FEP Females-FEP
Males (p = 0.04) and FEP Females-HC Males (p < 0.0001). There were no significant
correlations between FW and MCCB overall scores at baseline for either the male or female
FEP patients. FW values in both male and female FEP patients correlated significantly with
overall MCCB score at the 12-week follow-up (Male FEP r = 0.5247, Female FEP r =
0.4569) with no significant difference between the correlations (z = −0.22, p = 0.82).

D. Discussion
We report higher FW values in FEP patients compared to HC that are widespread,
encompassing multiple regions that have been previously implicated in the neurobiology of
schizophrenia. In contrast to widespread FW changes, we observed reductions in FA-t in
FEP patients only in circumscribed segments of the corpus callosum, left corona radiata, and
left superior longitudinal fasciculus. Among patients, higher FW was associated with better
cognitive functioning following 12 weeks of antipsychotic treatment.

Author Manuscript
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Our study demonstrates that lower FA in FEP, a finding previously reported in multiple
studies, is likely related to significant increases in FW (8,9). This result is consistent with
our prior findings in recent-onset schizophrenia patients (13) and indicates that extracellular
brain changes could serve as an indicator of early stage psychosis. One possible explanation
for higher FW at the first-episode of psychosis is a neuroinflammatory response, as
extracellular water volume is expected to be increased in neuroinflammatory states due to
the accumulation of water in the extracellular space (e.g., edema). Although we
acknowledge that other possible mechanisms could lead to greater extracellular water
volume, the neuroinflammation hypothesis is supported by considerable evidence that
abnormalities in the immune response may play a role in the pathophysiology of
schizophrenia. Data from diverse fields, including genetic (25–28), blood serology (29–31),
and postmortem studies (32,33) support the “inflammation hypothesis.” Moreover, a recent
genome-wide analysis implicated immune-related pathways as a principal risk factor in
schizophrenia (28) and studies of FEP patients report greater pro-inflammatory cytokines
and cytokine receptors (16,34,35).
While an increasing number of studies have identified the presence of a possible
neuroinflammatory response in schizophrenia, little is known regarding its functional
significance, especially early in psychosis. A prior study indicated that interleukin-6 levels
were negatively correlated with FA highlighting a potential mechanism for immune system
abnormalities in the neurobiology of white matter dysfunction in early-course clinically
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stabilized patients with schizophrenia (Prasad et al 2015)(36). Bulzacka and colleagues
(2016) also identified abnormally high C-reactive protein (CRP) levels in a subgroup of 104
chronic patients that were associated with impaired general intellectual ability (37).
Similarly, Dickerson and authors (2007) reported that higher CRP levels were associated
with worse functioning on the Repeatable Battery for the Assessment of Neuropsychological
Status compared to patients with lower CRP levels (38).

Author Manuscript
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We demonstrate that greater FW during the first-episode of psychosis has a positive
relationship with cognitive functioning following 12 weeks of antipsychotic treatment. This
correlation was uniquely related to FW, as reductions in FA-t observed at baseline in FEP
patients were unrelated to cognitive functioning. The finding of an increased, rather than a
decreased, FW response predicting better neurocognitive outcome may seem paradoxical
given that a majority of studies portray brain neuroinflammation in SZ as detrimental (39–
42). It is important to note, however, that while chronic inflammation is indeed a central part
of the majority of neurodegenerative brain disorders, acute neuroinflammatory responses are
usually intended to promote healing in cases of brain injury (43). Few studies have
investigated correlates of the neuroinflammatory response early in the course of illness in
relation to neurocognitive functioning. Taken together, our findings are consistent with the
hypothesis that the ability to mount an inflammatory response at the onset of psychosis may
portend a better neurocognitive outcome following antipsychotic treatment. Over the long
term, however, it is conceivable that an inability to resolve this response, and/or the
cumulative effect of chronic treatment with antipsychotic medications, may lead to white
matter abnormalities and neuropsychological dysfunction. Additionally, we found that
correlations between FW and MCCB domains were most robust for working and verbal
memory. These domains of functioning have consistently been demonstrated to be the most
impaired in schizophrenia (44,45) and have been identified as the most promising
endophenotypes for SZ because they are also observed among unaffected relatives (45,46).
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The relatively large number of female FEP offered the opportunity to explore sex effects.
Female FEP exhibited significantly increased FW values compared to female HC, male HC,
and male FEP. FEP males exhibited significant differences in FW when compared to male
healthy controls; however not to the same degree as the female FEP. Our FW findings
converge with a recent study reporting high levels of C-reactive protein (hsCRP), an acute
phase response immune marker in schizophrenia patients (47). These investigators
demonstrated greater levels of hsCRP in female patients compared to both female and male
controls, as well as male schizophrenia patients (47), suggesting there might be an increased
inflammatory response in the female patients’ brains relative to male patients’ brains. This is
particularly intriguing because much of the previous literature indicates that although males
and females have a similar incidence and prevalence of schizophrenia, females patients tend
to have lower relapse rates and higher pre- and post-morbid functioning (48). Based on the
results of our study, and the preceding study by Joseph and colleagues (47), an important
focus of future studies would be the further examination of sex differences in these
parameters.
There are several limitations of our study. The proportion of male and female participants
was not equal and larger sample sizes will be required to confirm findings of sex differences.
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Similarly, although we found no significant difference between patients minimally treated
with antipsychotics compared to antipsychotic drug-naïve patients in either FW or FA-t,
suggesting that short-term antipsychotic medication is not influencing the FW measure in
first-episode patients, these findings should be confirmed longitudinally in patients receiving
therapeutic dosages. Although no significant differences in baseline demographic or
cognitive variables were found between patients that remained in the study and those that
dropped out, we acknowledge the possibility that differential attrition could still conceivably
affect the results presented herein. Moreover, in the absence of longitudinal imaging data, it
is difficult to draw definitive conclusions about underlying biological correlates of the
observed cognitive outcomes in patients. Atypical antipsychotics have been shown to have
anti-inflammatory effects, which could be mediating the observed outcomes (16,49). As we
report no significant association between FW and neurocognitive performance at baseline
we conclude that greater baseline FW and subsequent antipsychotic treatment is associated
with better cognitive performance.
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We must also acknowledge that FW should be considered only a proxy for
neuroinflammation because it is an indirect measures of the neuroinflammatory response,
i.e., increased extracellular fractional volume (50). There are other possible underlying
biological pathologies previously reported in schizophrenia patients that could explain the
findings presented herein. These include pathologies such as decreased neuronal size (51),
which may be related to the reductions in FA-t, or atrophy due to excessive synaptic pruning
(52), which may contribute to the increased FW. Such pathology may, however, be more
likely identified in the gray matter and in patients at more chronic stages of illness (51,52).
Also, we note that the correlation between average whole brain FA and average whole brain
FW was r = −0.78. In the context of the Free Water Imaging model, we expect lower FA in
regions with higher FW in the absence of any reduction in FA-t. If there is a reduction in FAt, without concomitant changes in FW, this would also be reflected as lower FA in which
case FW would not be correlated with FA. Therefore, it is important to acknowledge that FA
and FW should not be simply construed as “mirror opposites.” Thus, the correlation between
these two measures suggests that the observed abnormality is related to an increase in
extracellular water, but not restricted/hindered water.
In summary, we find that lower FA in FEP can be explained primarily by greater FW, a
potential proxy for an acute neuroinflammatiory response. We present evidence that higher
FW at the first-episode of psychosis predicts better cognitive outcome following 12 weeks of
antipsychotic treatment. Additionally, we find that short-term antipsychotic treatment is not
related to extracellular FW increases or reductions in FA-t at baseline. Finally, we show that
sex can have a significant influence on FW in first-episode schizophrenia patients.

Author Manuscript
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Refer to Web version on PubMed Central for supplementary material.
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Widespread significant reductions in FA (A) appear to considerably overlap with significant
global increases in FW (B). Only limited reductions in FA-t are observed in first-episode
patients (C). No differences between medicated and medication- naïve patients were found
for FA, FW, or FA-t.
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Figure 2.

Average baseline FW values in first-episode patients show a significant positive correlation
with overall performance on the MCCB 12 weeks following antipsychotic treatment. This
suggests that greater FW values at the time of presentation of frank psychosis predict better
neurocognitive functioning 12 weeks later. This finding was unique to FW, as baseline FA-t
was not correlated with MCCB scores at either baseline or 12 weeks following treatment.
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Figure 3.

Our results show a significant influence of sex on the FW response at baseline. FW values
were significantly greater in female first-episode patients (n = 17) compared to male firstepisode patients (n = 46) as well as both male and female healthy controls. Male firstepisode patients also exhibited significantly greater FW values when compared to healthy
controls. There was no significant difference in the correlations between the overall MCCB
scores and FW values when comparing male and female FEP patients (See Table 2).
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Healthy Controls
Mean (SD)

First-Episode Patients
Mean (SD)

P-value

70

63

0.47

Males

46

46

Females

24

17

Total Sample (N)

Age (years)

21.51 (5.01)

21.38 (4.89)

0.8756

Edinburgh

0.6986 (0.47)

0.6967 (0.44)

0.9815

Education (years)

13.33 (2.69)

12.32 (1.91)

0.0129

Medication Status

Medicated

30 M/12 F

Medication-Naïve

16 M/5 F
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Pairwise Comparison of Mean for Sex by Diagnosis Groups: Tukey’s HSD
FW

Difference in Means

Adjusted P-value

FEP-F vs. HC-F

0.031

0.0004*

FEP-M vs. HC-M

0.014

0.023*

FEP-F vs. FEP-M

0.019

0.035*

FEP-F vs. HC-M

0.033

0.00002*

HC-F vs. FEP-M

−0.012

0.168

HC-F vs. HC-M

0.002

0.988

Author Manuscript
Author Manuscript
Author Manuscript
Mol Psychiatry. Author manuscript; available in PMC 2017 September 28.

